Metoprolol oxidation by rat liver microsomes. Inhibition by debrisoquine and other drugs.
The oxidative metabolism of metoprolol has been shown to display genetic polymorphism of the debrisoquine-type. The use of in vitro inhibition studies has been proposed as a means of defining whether one or more forms of cytochrome P-450 are involved in the monogenically-controlled metabolism of two substrates. We have, therefore, tested the ability of debrisoquine and other substrates to inhibit the oxidation of metoprolol by rat liver microsomes. Debrisoquine and guanoxan were potent competitive inhibitors of the alpha-hydroxylation and O-desmethylation of metoprolol as well as its metabolism by all routes (measured by substrate disappearance). Cimetidine and ranitidine, drugs which are known to impair the clearance of metoprolol in man, showed an inhibitory action comparable to that of debrisoquine in rat liver microsomes. Antipyrine, a compound whose metabolism is not impaired in poor metabolisers of debrisoquine, was found to be only a weak inhibitor of the metabolism of metoprolol. These findings suggest that the oxidation of metoprolol is linked closely to that of debrisoquine, cimetidine and ranitidine but not to that of antipyrine in the rat.
D000818:Animals; D000983:Antipyrine / Q000494:pharmacology; D002927:Cimetidine / Q000494:pharmacology; D003647:Debrisoquin / Q000494:pharmacology*; D006146:Guanidines / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology*; D008790:Metoprolol / Q000378:metabolism*; D008862:Microsomes, Liver / Q000378:metabolism*; D011899:Ranitidine / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains
D006146:Guanidines; D007546:Isoquinolines; D002927:Cimetidine; D011899:Ranitidine; D008790:Metoprolol; D000983:Antipyrine; D003647:Debrisoquin